Cleerly is touting study results regarding its Ischemia technology, published March 13 in the Journal of the American College of Cardiology: Cardiovascular Imaging.
The study describes the validation of Cleerly's AI-guided quantitative coronary CT angiography (AI-QCT) Ischemia technology for diagnostic accuracy and prognostic risk stratification. In two trials, the Credence and Pacific-1 studies comprised a total of 513 patients who underwent coronary CT angiography (CCTA), myocardial perfusion imaging with SPECT, and fractional flow reserve derived from CT (FFRCT).
The company highlighted that for patients with an abnormal Cleerly AI-QCT Ischemia finding, a positive result was associated with a nearly sevenfold increase of adverse cardiovascular events during an eight-year follow-up.
These study results come after Cleerly announced that its Cleerly Ischemia software device is billable using the new Category I CPT code 75580.
